Assignee
CHASE PHARMACEUTICALS CORP
US·13 granted patents·12 pending applications·51 citations·filing 2013–2019
Top patents by PatentIndex Score
25 records- 0193US9278092B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Mar 8, 2016·17 cites·14 claims
- 0292US9561218B2Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2013·Granted Feb 7, 2017·17 cites·3 claims
- 0385US9192591B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Nov 24, 2015·3 cites·22 claims
- 0484US9744161B2Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Aug 29, 2017·3 cites·38 claims
- 0583US9913836B2Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Mar 13, 2018·3 cites·11 claims
- 0682US10548855B2Memantine combinations and useCHASE PHARMACEUTICALS CORP·Filed 2017·Granted Feb 4, 2020·1 cites·8 claims
- 0782US9943508B2Method and composition for treating Alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2017·Granted Apr 17, 2018·2 cites·23 claims
- 0878US10307409B2Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous systemCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Jun 4, 2019·1 cites·3 claims
- 0977US10195187B2Oxybutynin-xanomeline transdermal therapeutic system combinationsCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Feb 5, 2019·1 cites·4 claims
- 1075US2020121656A1Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 1173US9896416B2Piperidinium quaternary saltsCHASE PHARMACEUTICALS CORP·Filed 2013·Granted Feb 20, 2018·1 cites·9 claims
- 1273US9044472B2Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2014·Granted Jun 2, 2015·1 cites·17 claims
- 1369US10149828B2Oxybutynin transdermal therapeutic system combinationCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Dec 11, 2018·1 cites·4 claims
- 1465US2020253893A1Memantine combinations and useCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 1563US2019091214A1Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 1662US2019365736A1Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 1762US2018296540A1Method and composition for treating alzheimer-type dementiaCHASE PHARMACEUTICALS CORP·Filed 2017·Application pending·0 cites
- 1862US2019314354A1Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous systemCHASE PHARMACEUTICALS CORP·Filed 2019·Application pending·0 cites
- 1961US2020171014A1Oxybutynin-xanomeline transdermal therapeutic system combinationsCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 2058US2019000826A1Anticholinergic neuroprotective composition and methodsCHASE PHARMACEUTICALS CORP·Filed 2018·Application pending·0 cites
- 2153US2015224096A1Use and composition for treating dementiaCHASE PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
- 2246US10596139B2Oxybutynin transdermal therapeutic system muscarinic agonist combinationCHASE PHARMACEUTICALS CORP·Filed 2016·Granted Mar 24, 2020·0 cites·6 claims
- 2343US2018360845A1Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disordersCHASE PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
- 2443US2018250270A1Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous systemCHASE PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
- 2542US2018050018A1Peripheral-anticholinergic muscarinic agonist combinationCHASE PHARMACEUTICALS CORP·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CHASE PHARMACEUTICALS CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →